{"id":"aminocaproic-acid","rwe":[],"_fda":{"id":"eea945f2-15ce-4ac9-b786-90f68f6e634c","set_id":"08bfb83e-3ac5-4e66-84a3-fcd4deaf73ae","openfda":{"nui":["N0000175634","N0000175632"],"upc":["0305179191253"],"unii":["U6F3787206"],"route":["INTRAVENOUS"],"rxcui":["238719"],"spl_id":["eea945f2-15ce-4ac9-b786-90f68f6e634c"],"brand_name":["Aminocaproic Acid"],"spl_set_id":["08bfb83e-3ac5-4e66-84a3-fcd4deaf73ae"],"package_ndc":["0517-9191-01","0517-9191-25"],"product_ndc":["0517-9191"],"generic_name":["AMINOCAPROIC ACID"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Decreased Fibrinolysis [PE]"],"substance_name":["AMINOCAPROIC ACID"],"pharm_class_epc":["Antifibrinolytic Agent [EPC]"],"manufacturer_name":["American Regent, Inc."],"application_number":["ANDA071192"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Aminocaproic Acid Injection, USP contains benzyl alcohol as a preservative. The administration of medications containing benzyl alcohol as a preservative to premature neonates has been associated with a fatal “Gasping Syndrome”. (See PRECAUTIONS, Pediatric Use. ) In patients with upper urinary tract bleeding, aminocaproic acid administration has been known to cause intrarenal obstruction in the form of glomerular capillary thrombosis or clots in the renal pelvis and ureters. For this reason, aminocaproic acid should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk. Subendocardial hemorrhages have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of aminocaproic acid and in monkeys given 8 times the maximum human therapeutic dose of aminocaproic acid. Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of aminocaproic acid at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of aminocaproic acid at 6 times the maximum human therapeutic dose. Rarely, skeletal muscle weakness with necrosis of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild myalgias with weakness and fatigue to a severe proximal myopathy with rhabdomyolysis, myoglobinuria, and acute renal failure. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. Aminocaproic acid administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of aminocaproic acid; however, the syndrome may recur if aminocaproic acid is restarted. The possibility of cardiac muscle damage should also be considered when skeletal myopathy occurs. One case of cardiac and hepatic lesions observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. Death was due to continued cerebrovascular hemorrhage. Necrotic changes in the heart and liver were noted at autopsy."],"pregnancy":["Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with aminocaproic acid. It is also not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE A few cases of acute overdosage with aminocaproic acid administered intravenously have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. One patient with a history of brain tumor and seizures experienced seizures after receiving an 8 gram bolus injection of aminocaproic acid. The single dose of aminocaproic acid causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while acute renal failure has been reported following a dose of 12 grams. The intravenous and oral LD 50 of aminocaproic acid were 3 and 12 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-clonic convulsions were observed in dogs and mice. No treatment for overdosage is known, although evidence exists that aminocaproic acid is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of aminocaproic acid is markedly decreased in patients with severe renal failure."],"references":["REFERENCES *Stefanini M. Dameshek W: The Hemorrhagic Disorders, Ed.2, New York, Grune and Stratton. 1962; pp. 510-514."],"description":["DESCRIPTION Aminocaproic Acid is 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis. The structural formula is: NH 2 CH 2 (CH 2 ) 3 CH 2 COOH The molecular formula is: C 6 H 13 NO 2 Molecular Weight: 131.17 Aminocaproic Acid is soluble in water, acid and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform. Aminocaproic Acid Injection, USP, for intravenous administration, is a sterile pyrogen-free solution containing 250 mg/mL of Aminocaproic Acid with Benzyl Alcohol 0.9%, as a preservative, and Water for Injection q.s. The pH is adjusted to approximately 6.8 with Hydrochloric Acid and/or Sodium Hydroxide."],"precautions":["PRECAUTIONS General Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).* Rapid intravenous administration of the drug should be avoided since this may induce hypotension, bradycardia, and/or arrhythmia. Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient’s preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed in vivo may not undergo spontaneous lysis as do normal clots. Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of antifibrinolytic agents in the treatment of subarachnoid hemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear. Thrombophlebitis, a possibility with all intravenous therapy, should be guarded against by strict attention to the proper insertion of the needle and the fixing of its position. Epsilon-aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased. Laboratory Tests The use of aminocaproic acid should be accompanied by tests designed to determine the amount of fibrinolysis present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin. DRUG & OR LABORATORY TEST INTERACTIONS Prolongation of the template bleeding time has been reported during continuous intravenous infusion of aminocaproic acid at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of aminocaproic acid, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of aminocaproic acid necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of aminocaproic acid may occur in patients with severe renal failure. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate the carcinogenic potential of aminocaproic acid and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of aminocaproic acid to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born. Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with aminocaproic acid. It is also not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Aminocaproic Acid Injection, USP contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal “gasping syndrome” in neonates. The “gasping syndrome”, characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine, has been associated with exposure to benzyl alcohol in neonates and low-birth weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse (see WARNINGS )."],"how_supplied":["HOW SUPPLIED Aminocaproic Acid Injection, USP, 250 mg/mL. For intravenous infusion after dilution. NDC 0517-9191-25 20 mL multiple dose vial Boxes of 25 Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). Manufactured by: American Regent, Inc. Shirley, NY 11967 Novaplus is a registered trademark of Vizient, Inc. IN9191 Rev. 05/2020 MG #44618"],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established. Aminocaproic Acid Injection, USP contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal “gasping syndrome” in neonates. The “gasping syndrome”, characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine, has been associated with exposure to benzyl alcohol in neonates and low-birth weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse (see WARNINGS )."],"effective_time":"20200716","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman."],"laboratory_tests":["Laboratory Tests The use of aminocaproic acid should be accompanied by tests designed to determine the amount of fibrinolysis present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin."],"adverse_reactions":["ADVERSE REACTIONS Aminocaproic acid is generally well tolerated. The following adverse experiences have been reported: General : Edema, headache, malaise. Hypersensitivity Reactions : Allergic and anaphylactoid reactions, anaphylaxis. Local Reactions : Injection site reactions, pain and necrosis. Cardiovascular : Bradycardia, hypotension, peripheral ischemia, thrombosis. Gastrointestina l: Abdominal pain, diarrhea, nausea, vomiting. Hematologic : Agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia. Musculoskeletal : CPK increased, muscle weakness, myalgia, myopathy (see WARNINGS ), myositis, rhabdomyolysis. Neurologic : Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope. Respiratory: Dyspnea, nasal congestion, pulmonary embolism. Skin : Pruritus, rash. Special Senses : Tinnitus, vision decreased, watery eyes. Urogenital : BUN increased, renal failure. There have been some reports of dry ejaculation during the period of aminocaproic acid treatment. These have been reported to date only in hemophilia patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy."],"contraindications":["CONTRAINDICATIONS Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."],"general_precautions":["General Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).* Rapid intravenous administration of the drug should be avoided since this may induce hypotension, bradycardia, and/or arrhythmia. Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient’s preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed in vivo may not undergo spontaneous lysis as do normal clots. Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of antifibrinolytic agents in the treatment of subarachnoid hemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear. Thrombophlebitis, a possibility with all intravenous therapy, should be guarded against by strict attention to the proper insertion of the needle and the fixing of its position. Epsilon-aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours. After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, aminocaproic acid has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells. Renal excretion is the primary route of elimination, whether aminocaproic acid is administered orally or intravenously. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for aminocaproic acid is approximately 2 hours."],"indications_and_usage":["INDICATIONS AND USAGE Aminocaproic Acid Injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, fresh whole blood transfusions, fibrinogen infusions, and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures), and portacaval shunt; hematological disorders such as aplastic anemia; acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may frequently be associated with life-threatening complications following severe trauma, anoxia, and shock. Symptomatic of such complications is surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .)"],"spl_unclassified_section":["Rx Only Novaplus Logo"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Aminocaproic Acid Injection, USP is administered by infusion, utilizing the usual compatible intravenous vehicles (e.g., Sterile Water for Injection, Sodium Chloride Injection 0.9%, Dextrose Injection 5% or Ringer’s Injection). Although Sterile Water for Injection is compatible for intravenous injection, the resultant solution is hypo-osmolar. RAPID INJECTION OF AMINOCAPROIC ACID INJECTION, USP UNDILUTED INTO A VEIN IS NOT RECOMMENDED. For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 16 to 20 mL (4 to 5 g) of Aminocaproic Acid Injection, USP in 250 mL of diluent be administered by infusion during the first hour of treatment, followed by a continuing infusion at the rate of 4 mL (1 g) per hour in 50 mL of diluent. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Oral Therapy: If the patient is able to take medication by mouth, an identical dosage regimen may be followed by administering aminocaproic acid tablets or aminocaproic acid syrup, 25% as follows: For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 grams of aminocaproic acid tablets or syrup be administered during the first hour of treatment, followed by a continuing rate of 1 gram of aminocaproic acid tablets or 1.25 grams of aminocaproic acid syrup per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled."],"spl_product_data_elements":["Aminocaproic Acid Aminocaproic Acid AMINOCAPROIC ACID AMINOCAPROIC ACID BENZYL ALCOHOL SODIUM HYDROXIDE HYDROCHLORIC ACID WATER"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL PRINCIPAL DISPLAY PANEL - 20 mL Container NDC 0517-9191-01 Rx ONLY Aminocaproic Acid Injection, USP For IV Infusion After Dilution 20 mL Multiple Dose Vial 5 g/20 mL (250 mg/20 mL) Manufactured by: American Regent, Inc., Shirley, NY 11967 Novaplus is a registered trademark of Vizient, Inc. PRINCIPAL DISPLAY PANEL – 20 mL Carton NDC 0517-9191-25 Rx ONLY Aminocaproic Acid Injection, USP For IV Infusion After Dilution 25 x 20 mL Multiple Dose Vial 5 g/20 mL (250 mg/mL) Manufactured by: American Regent, Inc., Shirley, NY 11967 Novaplus is a registered trademark of Vizient, Inc. Novaplus color logo Container Label Novaplus color logo Carton Labeling","Serialization Label Novaplus Serialization Label"],"drug_and_or_laboratory_test_interactions":["DRUG & OR LABORATORY TEST INTERACTIONS Prolongation of the template bleeding time has been reported during continuous intravenous infusion of aminocaproic acid at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of aminocaproic acid, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of aminocaproic acid necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of aminocaproic acid may occur in patients with severe renal failure."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate the carcinogenic potential of aminocaproic acid and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of aminocaproic acid to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born."]},"tags":[{"label":"Antifibrinolytic Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Plasminogen","category":"target"},{"label":"PLG","category":"gene"},{"label":"PLAT","category":"gene"},{"label":"B02AA01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Dental","category":"route"},{"label":"Gel","category":"form"},{"label":"Injection","category":"form"},{"label":"Paste","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Hyperfibrinolysis Induced Hemorrhage","category":"indication"},{"label":"Postsurgical Hemorrhage","category":"indication"},{"label":"Epic Pharma Llc","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Antifibrinolytic Agents","category":"pharmacology"},{"label":"Coagulants","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Hemostatics","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":201.115,"date":"","count":60,"signal":"Fear","source":"DrugCentral FAERS","actionTaken":"Reported 60 times (LLR=201)"},{"llr":183.112,"date":"","count":55,"signal":"Renal injury","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=183)"},{"llr":167.988,"date":"","count":71,"signal":"Unevaluable event","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=168)"},{"llr":163.947,"date":"","count":73,"signal":"Injury","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=164)"},{"llr":158.693,"date":"","count":46,"signal":"Anhedonia","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=159)"},{"llr":140.821,"date":"","count":53,"signal":"Emotional distress","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=141)"},{"llr":98.115,"date":"","count":73,"signal":"Renal failure","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=98)"},{"llr":90.071,"date":"","count":15,"signal":"Factor VIII inhibition","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=90)"},{"llr":85.877,"date":"","count":53,"signal":"Multiple organ dysfunction syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=86)"},{"llr":81.576,"date":"","count":72,"signal":"Anxiety","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=82)"},{"llr":76.79,"date":"","count":44,"signal":"Stress","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=77)"},{"llr":61.581,"date":"","count":49,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=62)"},{"llr":59.372,"date":"","count":23,"signal":"Product dispensing error","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=59)"},{"llr":46.23,"date":"","count":46,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=46)"},{"llr":43.768,"date":"","count":29,"signal":"Medication error","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=44)"}],"commonSideEffects":[{"effect":"Thrombosis","drugRate":"reported","severity":"unknown"},{"effect":"Renal failure","drugRate":"reported","severity":"serious"},{"effect":"Rhabdomyolysis","drugRate":"reported","severity":"serious"},{"effect":"Myopathy","drugRate":"reported","severity":"serious"},{"effect":"Myositis","drugRate":"reported","severity":"serious"},{"effect":"Myalgia","drugRate":"reported","severity":"mild"},{"effect":"Muscle weakness","drugRate":"reported","severity":"mild"},{"effect":"Nasal congestion","drugRate":"reported","severity":"mild"},{"effect":"Pulmonary embolism","drugRate":"reported","severity":"serious"},{"effect":"Pruritis","drugRate":"reported","severity":"mild"},{"effect":"Rash","drugRate":"reported","severity":"mild"},{"effect":"Stroke","drugRate":"reported","severity":"serious"},{"effect":"Syncope","drugRate":"reported","severity":"mild"},{"effect":"Tinnitus","drugRate":"reported","severity":"mild"},{"effect":"Vision decreased","drugRate":"reported","severity":"mild"},{"effect":"Watery eyes","drugRate":"reported","severity":"mild"},{"effect":"BUN increased","drugRate":"reported","severity":"unknown"},{"effect":"CPK increased","drugRate":"reported","severity":"unknown"},{"effect":"Coagulation disorder","drugRate":"reported","severity":"serious"},{"effect":"Leukopenia","drugRate":"reported","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"serious"},{"effect":"Convulsions","drugRate":"reported","severity":"serious"},{"effect":"Delirium","drugRate":"reported","severity":"serious"},{"effect":"Dizziness","drugRate":"reported","severity":"mild"},{"effect":"Hallucinations","drugRate":"reported","severity":"serious"},{"effect":"Intracranial hypertension","drugRate":"reported","severity":"serious"},{"effect":"Abdominal pain","drugRate":"reported","severity":"mild"},{"effect":"Diarrhea","drugRate":"reported","severity":"mild"},{"effect":"Nausea","drugRate":"reported","severity":"mild"},{"effect":"Vomiting","drugRate":"reported","severity":"mild"},{"effect":"Bradycardia","drugRate":"reported","severity":"serious"},{"effect":"Hypotension","drugRate":"reported","severity":"serious"},{"effect":"Peripheral ischemia","drugRate":"reported","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"reported","severity":"serious"},{"effect":"Allergic and anaphylactoid reactions","drugRate":"reported","severity":"serious"},{"effect":"Anaphylactoid reactions","drugRate":"reported","severity":"serious"},{"effect":"Edema","drugRate":"reported","severity":"mild"},{"effect":"Headache","drugRate":"reported","severity":"mild"},{"effect":"Malaise","drugRate":"reported","severity":"mild"}],"contraindications":["Blood in urine","Disease of liver","Disseminated intravascular coagulation","Increased Creatine Phosphokinase","Kidney disease","Thrombosis"],"specialPopulations":{"Pregnancy":"Aminocaproic acid should be given to pregnant woman only if clearly needed.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established. Aminocaproic Acid Injection, USP contains benzyl alcohol as preservative. Benzyl alcohol has been associated with fatal gasping syndrome in neonates."}},"trials":[],"aliases":[],"company":"Epic Pharma Llc","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$2.2439/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$808","description":"AMINOCAPROIC ACID 0.25 GRAM/ML","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMINOCAPROIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:02:26.253481+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:02:31.537773+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOCAPROIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:02:31.958984+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:02:25.138003+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:02:25.138043+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:02:25.138048+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tissue-type plasminogen activator inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:02:33.516466+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1046/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:02:33.173545+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA071192","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:02:25.138051+00:00"}},"allNames":"amicar","offLabel":[],"synonyms":["aminocaproic acid","6-Aminocaproic acid","6-Aminohexanoic acid","acepramin","epsilon-aminocaproic acid"],"timeline":[{"date":"1964-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CLOVER PHARMS to Epic Pharma Llc"},{"date":"1964-06-03","type":"positive","source":"DrugCentral","milestone":"FDA approval (Clover Pharms)"},{"date":"1982-10-29","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Baxter Hlthcare)"},{"date":"2021-04-08","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 13 manufacturers approved"}],"aiSummary":"Amicar, also known as ε-Aminocaproic Acid (EACA), is a medication used to treat conditions such as thrombocytopenia and hematological malignancies, as well as to reduce blood loss in surgeries like total knee replacement. It has also been studied as a potential treatment for conditions including osteoarthritis, pulmonary arterial hypertension, and coronavirus infection (COVID-19).","brandName":"Amicar","ecosystem":[{"indication":"Hyperfibrinolysis Induced Hemorrhage","otherDrugs":[],"globalPrevalence":null},{"indication":"Postsurgical Hemorrhage","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Plasminogen","novelty":"First-in-class","targets":[{"gene":"PLG","source":"DrugCentral","target":"Plasminogen","protein":"Plasminogen"},{"gene":"PLAT","source":"DrugCentral","target":"Tissue-type plasminogen activator","protein":"Tissue-type plasminogen activator"}],"modality":"Small Molecule","drugClass":"Antifibrinolytic Agent [EPC]","explanation":"","oneSentence":"","technicalDetail":"Amicar exerts its antifibrinolytic effects by competitively inhibiting the binding of plasminogen to its receptor, plasminogen activator, thereby preventing the conversion of plasminogen to plasmin and subsequent fibrinolysis."},"commercial":{"launchDate":"1964","_launchSource":"DrugCentral (FDA 1964-06-03, CLOVER PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/163","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMINOCAPROIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOCAPROIC ACID","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:41:02.520895","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:02:36.078596+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"tranexamic acid","drugSlug":"tranexamic-acid","fdaApproval":"1986-12-30","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"aminocaproic acid","indications":{"approved":[{"name":"Hyperfibrinolysis Induced Hemorrhage","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria available"},{"name":"Postsurgical Hemorrhage","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria available"}],"offLabel":[{"name":"Hemorrhaging in Hemophilia","source":"DrugCentral","drugName":"AMINOCAPROIC ACID"},{"name":"Prevention of Hemorrhage with Cardiovascular Instability from Cardiopulmonary Bypass - CABG","source":"DrugCentral","drugName":"AMINOCAPROIC ACID","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Prevention of Peri-Operative Hemorrhage","source":"DrugCentral","drugName":"AMINOCAPROIC ACID","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Epic Pharma Llc","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"tranexamic-acid","brandName":"tranexamic acid","genericName":"tranexamic acid","approvalYear":"1986","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT02229968","phase":"PHASE2","title":"Efficacy of Amicar for Children Having Craniofacial Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2014-10","conditions":["Craniosynostosis"],"enrollment":22,"completionDate":"2027-03"},{"nctId":"NCT05338008","phase":"NA","title":"Intrawound Administration of Vancomycin in THA","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-05-01","conditions":["Hip"],"enrollment":120,"completionDate":"2022-12-31"},{"nctId":"NCT06493227","phase":"NA","title":"Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-08-01","conditions":["Thoracic Surgery","Heart Diseases","Fibrinolysis Shutdown"],"enrollment":1373,"completionDate":"2026-06-01"},{"nctId":"NCT02656472","phase":"PHASE4","title":"A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-02","conditions":["Pediatric Cardiac Surgery","Complication of Extracorporeal Circulation"],"enrollment":22,"completionDate":"2017-04"},{"nctId":"NCT04814433","phase":"PHASE4","title":"Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2021-03-24","conditions":["Opioid Pain Medication"],"enrollment":46,"completionDate":"2023-07-10"},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":["Adenovirus","Anesthesia","Anxiety","Anxiolysis","Autism","Autistic Disorder","Bacterial Meningitis","Bacterial Septicemia","Benzodiazepine","Bipolar Disorder","Bone and Joint Infections","Central Nervous System Infections","Convulsions","Cytomegalovirus Retinitis","Early-onset Schizophrenia Spectrum Disorders","Epilepsy","General Anesthesia","Gynecologic Infections","Herpes Simplex Virus","Infantile Hemangioma","Infection","Inflammation","Inflammatory Conditions","Intra-abdominal Infections","Lower Respiratory Tract Infections","Migraines","Pain","Pneumonia","Schizophrenia","Sedation","Seizures","Skeletal Muscle Spasms","Skin and Skin-structure Infections","Treatment-resistant Schizophrenia","Urinary Tract Infections","Withdrawal","Sepsis","Gram-negative Infection","Bradycardia","Cardiac Arrest","Cardiac Arrhythmia","Staphylococcal Infections","Nosocomial Pneumonia","Neuromuscular Blockade","Methicillin Resistant Staphylococcus Aureus","Endocarditis","Neutropenia","Headache","Fibrinolytic Bleeding","Pulmonary Arterial Hypertension","CMV Retinitis","Hypertension","Chronic Kidney Diseases","Hyperaldosteronism","Hypokalemia","Heart Failure","Hemophilia","Heavy Menstrual Bleeding","Insomnia"],"enrollment":3520,"completionDate":"2019-11"},{"nctId":"NCT05338021","phase":"NA","title":"Intrawound Administration of Vancomycin in TKA","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-05-25","conditions":["Knee Osteoarthritis"],"enrollment":100,"completionDate":"2022-09-07"},{"nctId":"NCT02257580","phase":"PHASE4","title":"The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2015-04-01","conditions":["E-Aminocaproic Acid","Bilateral Varus Rotational Osteotomy"],"enrollment":28,"completionDate":"2020-10-26"},{"nctId":"NCT02074436","phase":"PHASE2","title":"PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)","status":"TERMINATED","sponsor":"Emory University","startDate":"2014-05-23","conditions":["Hematological Malignancies","Thrombocytopenia"],"enrollment":29,"completionDate":"2021-05-14"},{"nctId":"NCT05291312","phase":"NA","title":"EACA VS CCA in Postoperative Evaluation of Middle Ear Pressure","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-05-01","conditions":["Adenoid Hypertrophy"],"enrollment":70,"completionDate":"2024-12-01"},{"nctId":"NCT04187014","phase":"PHASE2","title":"Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement","status":"COMPLETED","sponsor":"Carlos A Acosta-Olivo","startDate":"2020-02-06","conditions":["Blood Loss, Surgical"],"enrollment":90,"completionDate":"2021-04-26"},{"nctId":"NCT01248104","phase":"NA","title":"Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2010-03","conditions":["Cardiopulmonary Bypass"],"enrollment":100,"completionDate":"2015-02"},{"nctId":"NCT02655653","phase":"PHASE3","title":"Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2008-10","conditions":["Bleeding"],"enrollment":114,"completionDate":"2015-10"},{"nctId":"NCT04424563","phase":"","title":"Activated Factor Seven in Traumatic Retro Peritoneal Hematoma","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2017-05-05","conditions":["Traumatic Bleeding"],"enrollment":80,"completionDate":"2019-12-30"},{"nctId":"NCT01971684","phase":"","title":"ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-08","conditions":["Immune Thrombocytopenia"],"enrollment":120,"completionDate":"2017-04"},{"nctId":"NCT01398280","phase":"EARLY_PHASE1","title":"Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-07","conditions":["Rosacea"],"enrollment":15,"completionDate":"2012-12"},{"nctId":"NCT03365999","phase":"PHASE2","title":"Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.","status":"COMPLETED","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2017-10-15","conditions":["Knee Osteoarthritis","Blood Clot","Transfusion Related Complication","Blood Loss"],"enrollment":92,"completionDate":"2019-07-01"},{"nctId":"NCT01965730","phase":"EARLY_PHASE1","title":"Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2013-01","conditions":["Aortic Disease"],"enrollment":8,"completionDate":"2014-06"},{"nctId":"NCT02030821","phase":"PHASE4","title":"TXA vs. Amicar in Total Knee and Hip Arthroplasty","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":["Blood Loss","Hip Arthritis","Knee Arthritis"],"enrollment":246,"completionDate":"2017-11-12"},{"nctId":"NCT00958581","phase":"PHASE4","title":"Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-12","conditions":["Scoliosis"],"enrollment":177,"completionDate":"2012-09"},{"nctId":"NCT02352675","phase":"","title":"Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2015-04","conditions":["Congenital Heart Disease","Fibrinolysis","Rotational Thromboelastometry"],"enrollment":40,"completionDate":"2016-03"},{"nctId":"NCT02639819","phase":"PHASE1","title":"Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-06","conditions":["Intracerebral Hemorrhage"],"enrollment":0,"completionDate":"2017-12"},{"nctId":"NCT00320619","phase":"NA","title":"Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2000-09","conditions":["Scoliosis","Kyphosis","Lordosis","Spondylitis","Spinal Stenosis"],"enrollment":182,"completionDate":"2006-02"},{"nctId":"NCT01527968","phase":"NA","title":"Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Heekin Orthopedic Research Institute","startDate":"2012-04","conditions":["Osteoarthritis"],"enrollment":54,"completionDate":"2016-12"},{"nctId":"NCT01981863","phase":"PHASE4","title":"Fibrinolysis Before Cardiopulmonary Bypass?","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-07","conditions":["Pathologic Fibrinolysis"],"enrollment":40,"completionDate":"2014-02"},{"nctId":"NCT00617955","phase":"","title":"Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2007-09","conditions":["Cardiac Surgery"],"enrollment":462,"completionDate":"2009-06"},{"nctId":"NCT01873768","phase":"PHASE4","title":"Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement","status":"COMPLETED","sponsor":"Miller Orthopedic Specialists","startDate":"2014-01","conditions":["Osteoarthritis"],"enrollment":194,"completionDate":"2015-12"},{"nctId":"NCT02616042","phase":"PHASE3","title":"The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis","status":"COMPLETED","sponsor":"LG Household & Health Care Ltd.","startDate":"2009-03","conditions":["Labor Trial Refused"],"enrollment":33,"completionDate":"2009-12"},{"nctId":"NCT01391182","phase":"NA","title":"Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-07","conditions":["Degenerative Joint Disease","Osteoarthritis"],"enrollment":60,"completionDate":"2015-01"},{"nctId":"NCT02238288","phase":"PHASE4","title":"Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients","status":"UNKNOWN","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2013-12","conditions":["Oral Hemorrhage"],"enrollment":154,"completionDate":"2015-07"},{"nctId":"NCT00223704","phase":"PHASE2,PHASE3","title":"Bradykinin Receptor Antagonism During Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2006-05","conditions":["Cardiopulmonary Bypass","Inflammation","Fibrinolysis","Surgery"],"enrollment":150,"completionDate":"2012-06"},{"nctId":"NCT01408823","phase":"","title":"Pharmacokinetics of Aminocaproic Acid in Scoliosis Surgery","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2011-07","conditions":["Scoliosis"],"enrollment":20,"completionDate":"2011-10"},{"nctId":"NCT00912119","phase":"PHASE1","title":"Amicar Pharmacokinetics of Children Having Craniofacial Surgery","status":"COMPLETED","sponsor":"Paul Stricker","startDate":"2009-05","conditions":["Craniosynostosis"],"enrollment":18,"completionDate":"2011-10"},{"nctId":"NCT00156520","phase":"PHASE4","title":"Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2005-03","conditions":["Hemorrhage"],"enrollment":40,"completionDate":"2005-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Gel, Injection, Paste","formulations":[{"form":"GEL, DENTIFRICE","route":"ORAL","productName":"ROOTSALLO TOOTHPASTE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"AMINOCAPROIC ACID"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminocaproic Acid"},{"form":"PASTE","route":"DENTAL","productName":"BAMBOO SALT  Eunganggo Jook Yeom"},{"form":"PASTE","route":"DENTAL","productName":"BAMBOO SALT  Eunganggo Jook Yeom Toothpaste"},{"form":"PASTE","route":"ORAL","productName":"Hae Yan Tooth"},{"form":"PASTE","route":"ORAL","productName":"HiMangChanToothpaste"},{"form":"PASTE","route":"ORAL","productName":"Solco Platino Iondenti Tooth"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"CLEAN BREATH TOOTH"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"Dr.EL GUM CARE TOOTH"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"GRAY SALT TOOTH"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"GREENSALTRAIN TOOTH"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"Gray Salt Tooth"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"Hea YanToothpaste"},{"form":"PASTE, DENTIFRICE","route":"DENTAL","productName":"Mastikis Mastic 24K"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000170207","MMSL":"4169","NDDF":"002072","UNII":"U6F3787206","VUID":"4017911","CHEBI":"CHEBI:16586","VANDF":"4017911","INN_ID":"1189","RXNORM":"99","UMLSCUI":"C0000608","chemblId":"CHEMBL1046","ChEMBL_ID":"CHEMBL1046","KEGG_DRUG":"D00160","DRUGBANK_ID":"DB00513","PDB_CHEM_ID":" ACA","PUBCHEM_CID":"564","SNOMEDCT_US":"360246003","IUPHAR_LIGAND_ID":"6574","MESH_DESCRIPTOR_UI":"D015119"},"formularyStatus":[],"originalProduct":{"form":"SOLUTION","route":"ORAL","company":"Clover Pharmaceuticals Corp.","brandName":"AMICAR","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1964-","companyName":"Clover Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Epic Pharma Llc","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.9 hours","clearance":"2.5 mL/min/kg","fractionUnbound":"0.92%","volumeOfDistribution":"0.39 L/kg"},"publicationCount":2572,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B02AA01","allCodes":["B02AA01"]},"biosimilarFilings":[],"originalDeveloper":"Clover Pharms","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":21,"_genericFilersChecked":true,"genericManufacturerList":["Abraxis Pharm","Adaptis","Ajenat Pharms","Amneal","Ani Pharms","Annora Pharma","Aurobindo Pharma","Carnegie","Epic Pharma Llc","Gen Ilac","Hikma","Hospira","Luitpold","Msn","Regcon Holdings","Sciegen Pharms","Somerset Theraps Llc","Sunny","Taro","Tp Anda Holdings","Vistapharm Llc"],"status":"approved","companyName":"Epic Pharma Llc","companyId":"epic-pharma-llc","modality":"Small molecule","firstApprovalDate":"1964","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-06-17T00:00:00.000Z","mah":"ABRAXIS PHARM","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA070522"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-03-09T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":"AMINOCAPROIC ACID IN PLASTIC CONTAINER","application_number":"ANDA070010"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-12-01T00:00:00.000Z","mah":"LUITPOLD","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA071192"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-09-02T00:00:00.000Z","mah":"EPIC PHARMA LLC","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA074759"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-05-24T00:00:00.000Z","mah":"HIKMA","brand_name_local":"AMINOCAPROIC","application_number":"ANDA075602"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-27T00:00:00.000Z","mah":"SUNNY","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA209060"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-23T00:00:00.000Z","mah":"AMNEAL","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA212780"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-11-26T00:00:00.000Z","mah":"AMNEAL","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA212492"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-02-26T00:00:00.000Z","mah":"VISTAPHARM LLC","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA212814"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-08-11T00:00:00.000Z","mah":"TP ANDA HOLDINGS","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA212494"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-11-06T00:00:00.000Z","mah":"MSN","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA212938"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-01-26T00:00:00.000Z","mah":"CARNEGIE","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA214140"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-02-12T00:00:00.000Z","mah":"CARNEGIE","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA213928"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-06-14T00:00:00.000Z","mah":"ADAPTIS","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA212110"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-09-14T00:00:00.000Z","mah":"SOMERSET THERAPS LLC","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA213944"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-11-04T00:00:00.000Z","mah":"ANNORA PHARMA","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA216464"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-24T00:00:00.000Z","mah":"TARO","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA214458"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-12-27T00:00:00.000Z","mah":"SUNNY","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA213213"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-09-26T00:00:00.000Z","mah":"MSN","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA215100"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-05-19T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA213216"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-28T00:00:00.000Z","mah":"ZENARA","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA215374"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"QUAD PHARMS","brand_name_local":"AMINOCAPROIC ACID","application_number":"ANDA070694"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:02:36.078596+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}